Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says

Executive Summary

Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.

You may also be interested in...



Medicare Coverage-In-Clinical-Trials Policy For Alzheimer’s Drugs Could Stifle Access For Years

Proposed Medicare national coverage policy would delay access to Alzheimer’s drugs for too long and the government should instead cover the drugs under specific conditions until research already underway comes in, Global Alzheimer’s Platform Foundation president John Dwyer argues.

Biogen Pledges Aduhelm Confirmatory Data By 2026, Renewing Spotlight On FDA’s Lengthy Original Plan

Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is much faster than the nine years required by US FDA under the accelerated approval.

Biogen Expects Confirmatory Aduhelm Data In 2026, But Is It Too Late?

Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is faster than the nine years required by FDA under the accelerated approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel